{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:47:45Z","timestamp":1775638065699,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are few nationwide descriptive studies of longitudinal drug use and residual cardiovascular risk in patients with myocardial infarction (MI) in contemporary clinical practice. The objectives of this work were to describe characteristics and longitudinal cardiovascular drug use of patients with a first acute MI in Norway, and to quantify residual risks of cardiovascular events and death. Using nationwide health registries in Norway, we identified 43\u2009750 adults with a first MI (2010 to 2015) and \u22651 prescription for antiplatelet medication. We described cardiovascular medication post\u2010MI and calculated residual cardiovascular risks. Between 3\u2009months and 13\u201315\u2009months post MI, medication use dropped from 93.3% to 75.1% for low\u2010dose aspirin, 78.1% to 11.0% for dual antiplatelet therapy, 91.6% to 78.7% for antihypertensives, and 88.0% to 70.7% for lipid\u2010lowering therapy. Incidence rate ratios (IRRs) for recurrent MI were similar between subpopulations at 12\u2009months and notably different at 12\u201336\u2009months. IRRs (95% CIs) at 12\u201336\u2009months were 1.52 (1.26\u20131.82) for 65\u201374\u2009years, 2.26 (1.88\u20132.71) for 75\u201384\u2009years, and 3.97 (3.29\u20134.79) for \u226585\u2009years (vs. 18\u201349\u2009years), 2.42 (2.18\u20132.69) for those with ischaemic heart disease (IHD), 2.26 (1.97\u20132.59) for peripheral artery disease (PAD), 2.17 (1.98\u20132.36) for hypertension, and 1.82 (1.65\u20132.01) for diabetes. In conclusion, secondary prevention medication use 13\u201315\u2009months following a first MI is suboptimal among patients in Norway. The elderly and those with IHD, PAD, diabetes, or hypertension are at high\u2010risk for recurrent MI\/stroke\/death and should be managed closely beyond the first year.<\/jats:p>","DOI":"10.1111\/fcp.12744","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T11:15:17Z","timestamp":1639480517000},"page":"563-571","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characteristics, treatment patterns, and residual cardiovascular risk of patients with a first acute myocardial infarction: A nationwide population\u2010based cohort study in Norway"],"prefix":"10.1111","volume":"36","author":[{"given":"Nikolaus G.","family":"Oberprieler","sequence":"first","affiliation":[{"name":"Integrated Evidence Generation &amp; Business Innovation Bayer AS  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahman","family":"Farahmand","sequence":"additional","affiliation":[{"name":"Integrated Evidence Generation &amp; Business Innovation Bayer AB  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Cameron","sequence":"additional","affiliation":[{"name":"Medical Affairs Bayer AS  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Brobert","sequence":"additional","affiliation":[{"name":"Integrated Evidence Generation &amp; Business Innovation Bayer AB  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Jonasson","sequence":"additional","affiliation":[{"name":"KG Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Science NTNU\u2014Norwegian University of Science and Technology  Trondheim Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-8793","authenticated-orcid":false,"given":"Dan","family":"Atar","sequence":"additional","affiliation":[{"name":"Department of Cardiology Oslo University Hospital Ullev\u00e5l  Oslo Norway"},{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw334"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487316663873"},{"key":"e_1_2_10_4_1","volume-title":"Public Health Report","author":"Norwegian Institute of Public Health","year":"2020"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.016960"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.15829\/1560\u20104071\u20102021\u20104418"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872\u2010019\u20101062\u2010y"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.01.004"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102261\u201014\u20104"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494819859737"},{"key":"e_1_2_10_12_1","unstructured":"Norwegian Institute of Public Health.Norwegian Prescription Database.https:\/\/www.fhi.no\/en\/hn\/health-registries\/norpd\/. Accessed 29 November 2021"},{"key":"e_1_2_10_13_1","article-title":"Pharmacy\u2010dispensed drugs for secondary prevention after myocardial infarction","volume":"140","author":"Jortveit J","year":"2020","journal-title":"J nor Med Ass"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872\u2010016\u20100400\u20106"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872\u2010016\u20100283\u20106"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.11.012"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010013\u20101614\u20105"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569\u2010019\u20100233\u2010y"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu505"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2020.12.013"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2021.04.008"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12744","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.12744","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T18:04:26Z","timestamp":1692986666000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/fcp.12744"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12744","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"assertion":[{"value":"2021-09-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}